Turoctocog alfa pegol versus recombinant factor VIII-Fc fusion protein: a head-to-head pharmacokinetics comparison

Abstract

Our series of five cases enabled a direct comparison of the pharmacokinetic (PK) profiles of turoctocog alfa pegol versus efmoroctocog alfa, a recombinant a factor VIII‐Fc fusion protein, performed in the same subjects with severe hemophilia A within a short time-frame. Half-life values were significantly longer, by about 1 hour, with turoctocog alfa pegol than with efmoroctocog alfa. The estimated time spent with FVIII levels above 5% when infusing every 4 days was significantly longer with turoctocog alfa pegol. When feasible, the possibility of executing a PK curve should be considered, in order to use the parameters obtained as the main indicators and predictors of coagulation support.